Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase 2b Study

NCT03089138 is registered in ClinicalTrials.gov with Beijing Da-an Bio-technology Co., Ltd. as lead sponsor.

NCT NCT03089138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03089138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase 2b Study
Lead sponsor
Beijing Da-an Bio-technology Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2017
Completion date
March 31, 2018
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cold